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 Oral mucositis (OM) caused by ionizing radiation is a significant therapeutic problem concerning almost all patients with 
head and neck cancers undergoing irradiation, however, an effective treatment method is still missing. Therapeutic ac-
tions concentrate mostly on prophylaxis, including the maintenance of the correct hygiene of the oral cavity. In 2014 the 
International Society of Oral Oncology (ISOO) together with the (Multinational Association of Supportive Care in Cancer 
(MASCC) worked out the guidelines for the treatment of patients with z OM induced by radiotherapy and chemotherapy. 
In 2019 these guidelines were updated.
 Research is ongoing to find medication which could be applicable for the prevention and treatment of OM. The problem 
is grave as it might complicate the progress of oncological treatment, deteriorate the patient’s quality of life or even affect 
the prognosis.
 This paper describes the pathogenesis of oral mucositis, the current trends in treatment and discusses the role of a dentistry 
doctors in the care of the patient with symptoms of this condition. The article also refers to the role of a multidisciplinary 
team – the OM prophylaxis – as part of the preparation of an oncological patient for irradiation.
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Introduction 
Unaffected oral mucosa makes up the best protection aga-
inst pathogens and other external factors. In the majority 
of patients, the lesions of the oral mucosa – irrespective of 
their origin – cause significant discomfort, as they are usually 
accompanied by pain and difficulties in chewing and swallo-
wing. In recent years, on account of  the growing number of 
patients receiving the anti-cancer treatment and due to their 
prolonged duration of life, the number of patients contacting 
dentists due to various complains about the condition of oral 
mucosa caused by complications arising from oncological 
treatment has increased.
Malignant cancers are one of the main causes of death 
in Poland and worldwide. According to the National Cancer 
Register, the incidence of malignant tumours in Poland, in 
the last 30 years has doubled, whilst the number of deaths 
within the last 50 years has increased 2.4-fold. [1]. Cancers 
located in the area of the head and neck account for between 
5.5% and 6.2% of all malignant cancers in Poland. Other Eu-
ropean countries and the United States have noted similar 
prevalence rates [2]. The basic methods of treatment in the 
case of this type of cancer comprise surgery and radiotherapy 
– often combined with systemic treatment. However, the use 
of irradiation is connected with the risk of development of 
oral mucositis (OM), which might be exacerbated in patients 
undergoing chemotherapy together with radiotherapy. OM 
is induced by ionising irradiation and is regarded as one of 
post-radiation acute reactions. It concerns almost all patients 
undergoing chemotherapy in the area of the head and neck 
[4, 5, 7–10 ]. Such a reaction was described for the first time 
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in 1980 in patients with head and neck cancers undergoing 
radiotherapy [5, 6]. In 2007 the World Health Organization 
(WHO) considered oral mucositis as a separate disease unit 
[3, 4].
Patomechanism 
OM is caused by mechanisms which directly and indirectly 
affect the cells of the oral epithelium, including their division 
and maturation [5]. The direct impact of irradiation is con-
nected with apoptosis induction [5, 11]. Indirect mechanisms 
consist in the release of proinflammatory mediators with 
simultaneous reduction of the release of anti-inflammatory 
mediators in the cells of the oral epithelium [5]. Sonis worked 
out the five-stage model of OM development induced by 
radio- and chemotherapy [3]. In the first stage, called the 
initiation stage, direct DNA damage occurs and reactive 
oxygen species (ROS) are released. [3, 12, 13]. The second 
stage is called  signalling: in this stage transcription factors, 
such as NF-kB, are activated. As a result of complex biolog-
ical processes, the number of proinflammatory cytokines 
– such as TNF-α, IL-1-β, IL-6 – increases [3, 5, 14], whereas, at 
the same time, the number of anti-inflammatory cytokines, 
such as IL-10 and TGF-β decreases [3, 14]. As a result of 
the expression of more than 200 various genes, the mole-
cules responsible for epithelial damage and the activation 
of other molecular pathways are produced [3]. It must be 
emphasised that the NF-kB protein complex plays a main 
role in the development of radiotherapy induced OM. OM 
may develop directly under the influence of chemotherapy 
or radiotherapy, and indirectly – by ROS [3, 6, 12]. The effect 
of the activation of this pathway may be programmed cell 
death by means of apoptosis  [3]. The third stage of OM 
development is amplification, i.e. m signal magnification. 
At this point the inflammatory cascade is activated. The 
clinical manifestation is comprised of oedema and erythema 
caused by the activation of proinflammatory cytokines  [3]. 
The fourth phase – ulceration – is regarded as the most 
significant with respect to its clinical picture [3]. The rapid de-
velopment of biological processes leads to the apoptosis of 
the epithelial cells. Deep, clinically overt ulceration develops 
and this might easily be colonised by pathogens. Bacteria 
cause mucositis, whilst the products of the lysis of the cellular 
walls penetrate to the submucosal membrane, increasing 
the proinflammatory effect. After the penetration of living 
bacteria into the blood vessels in the submucosal layer of 
the mucosal membrane, inflammation might develop into 
a systemic infection (sepsis). The risk of sepsis, originating in 
the oral cavity is especially present in patients with additional 
risk factors, such as granulocytopenia induced by anti-can-
cer treatment [6, 12]. The fifth phase of the OM evolution 
patomechanism is healing [12]. The majority of cases of 
oral mucositis, thanks to biological reparatory pathways, are 
spontaneously healed [3].
Risk factors and location of the lesions    
There are risk factors which predispose the development of 
OM: their analysis facilitates taking preventive steps and the 
definition of therapeutic goals [3]. The OM risk factors comprise:
• poor hygiene status of the oral cavity,
• the presence of defects caused by dental caries,
• lesions of the oral mucosa,
• tobacco smoking,
• poor nutritional status,
• systemic comorbidities (e.g. neutropenia), 
• folic acid and B12 vitamin deficit,
• oral cavity dryness,
• some medication (e.g. cytotoxic drugs with muco-toxic 
action),
• age (the risk is higher before 20 and after 50 years of age),
• sex (OM is more frequent in women),
• genetic factors (np. MTHFR C677T nucleotide polymor-
phism in patients treated with methotrexate) [5, 9, 10].
Lesions connected with OM are located mainly in the 
movable, non-keratinising mucosa. They affect mostly the 
buccal mucosa, the inside surface of the lips, the lateral and 
ventral side of the tongue, the fundus of the oral cavity, soft 
palate and pharynx mucosa [3, 7, 15, 16].
The course of the disease
The one of the main symptom of OM is a burning sensation in 
the oral cavity. Ulceration is deeper than in the case of aphthous 
stomatitis and makes a gateway for bacterial infection (Gram+ 
and Gram–) infections. Opportunistic infections (OIs) may hin-
der diagnosis and treatment [3, 11, 15]. Within the course of oral 
mucositis, the probability of infections increases – not only of 
bacterial origin, but also mycotic or viral [11, 17]. The infections 
are also stimulated by decreased saliva production caused by 
the anti-cancer treatment (damage of salivary glands) and 
neutropenia [3, 5, 9, 18].
In patients suffering from head and neck cancers, the 
lesions induced by OM may vary with regards to their inten-
sity, depending, among others on the irradiation dose and its 
possible combination with chemotherapy [9, 11]. 
Oral mucositis may lead not only to difficulties in food 
consumption, but also in everyday life [19]. The immunity of 
these patients is compromised, and thus the risk of developing 
other diseases, also in the oral region, is greater [15]. Loss of 
body weight or emaciation of the whole organism as well as 
resulting outcomes such as sepsis and death are likely [12]. The 
total duration of treatment and hospital stay are longer, more 
medication is required, and the patient needs interventions 
in hospital more frequently [5]. Also the economic outcomes 
of OM are significant for the healthcare system [5, 10]. OM 
symptoms also impair the patient’s quality of life and may lead 
to depression and social isolation resulting from problems 
with food intake and speech [5]. Moreover the quality of life 
is decreased and swallowing problems can occur. In such 
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Honey has an antibacterial and anti-inflammatory action 
[30], and, according to some experimental research, inhibits 
the initiation of  NF-kB [14, 26].
Despite the extensive research which provides very posi-
tive evaluations of the above substances, available literature 
lacks any clear recommendations concerning their use in OM 
prevention and treatment in patients with head and neck can-
cers undergoing chemotherapy or radiotherapy. Prospective 
trials conducted on large groups of patients are necessary. 
In 2014, the International Society of Oral Oncology (ISOO) 
and the Multinational Association of Supportive Care in Can-
cer (MASCC) published guidelines for treating patients with 
OM. The authors emphasise the role of oral hygiene in the 
prevention of the disease. They pay special attention to teeth 
brushing and rinsing the oral cavity [6, 8, 16].
In June 2019, the guidelines of MASCC/ISOO were updated 
and this revised version confirmed the previous guidelines 
concerning the basic rules of oral hygiene in OM prevention. 
The benefits from  patients education were emphasised [28]. 
The study group MASCC/ISOO based this update on 9 source 
articles, 8 of which concern OM prophylaxis and treatment. The 
review concerned the principles of oral cavity care, the role of 
anti-inflammatory agents, natural substances, vitamins, dietary 
supplements, photo-biomodulation, and  oral hygiene (tab. II). 
However, many binding guidelines have remained unchanged. 
The need for further research was stressed which might affect 
the next update of the guidelines [28–32].
What draws attention in the MASCC/ISOO guidelines from 
2019 is an important change concerning the use of zinc and 
glutamine administered systemically [16, 31]. It is stressed that 
zinc is necessary for the correct functioning of the immune 
system and antibody production, as it has the ability to remove 
superoxide free radicals [9]. Benzydamine, in turn is a non-
-steroid anti-inflammatory drug – its efficacy has been proven 
in patients after irradiation treatment [22].
No recommendations concerning the administration of 
zinc, supersaturated  calcium phosphate rinse (SCPR), an ele-
mental diet and vitamin E [31] in the prevention of OM in 
patients with head and neck cancers undergoing RT and/or 
RT-CT were made. However, there was a suggestion of oral 
administration of glutamine in patients undergoing radiothe-
rapy in order to prevent the development of OM. It must be 
remembered, however, that patients suffering from MS who are 
treated with hematopoietic stem cell transplantation (HSCT), 
should be administered glutamine with caution. In patients 
who received glutamine systemically, some treatment failures 
have occurred [31]. 
As a result of the lack of adequate number of trials, MA-
SCC/ISOO did not publish any guidelines concerning the use 
of anti-inflammatory drugs, such as celexibe, misoprostol or 
rebamipide, for the prevention of OM in patients with head 
and neck cancers. In the OM prophylaxis, experts recommend 
rinsing the oral cavity with benzydamine in patients receiving 
situations it is necessary to modify the anti-cancer treatment 
or even completely discontinue it, which can certainly lead to 
rather adverse outcomes [5, 9, 10].
Diagnosis 
There are many classifications applied for the evaluation of the 
intensity of OM [3]. The majority of centres base their evaluation 
on the five-grade scale worked by the WHO [15] (tab. I).
In order to make a quick diagnosis of OM, it is necessary to 
make a frequent and detailed physical examination and take 
a detailed history of the patients undergoing radiotherapy. The 
time of symptom occurrence and the intensity of OM must be 
monitored during therapy [11]. 
Prevention and treatment
So far, no effective method of OM treatment has been intro-
duced [22], that is why a key role is played by prophylaxis [9]. 
The preventive actions concentrate in the improvement and 
maintenance of the correct oral cavity hygiene and sympto-
matic treatment [22]. Laser therapy  and cryo-therapy play an 
important role. In patients undergoing chemotherapy, Bockel 
et al. used laser therapy 2–3 times per week with a low power 
laser (630–660 nm) and obtained good therapeutic effects [13]. 
Daugėlaitė et al., in 2019 published a metanalysis of research 
papers concerning OM treatment published in 2007–2017 
[22]. The authors described the substances used for prevention 
and treatment of OM, comprising, among others: a balm with 
Lactobacillus Brevis or royal jelly [22]. Other substances helpful 
in the treatment of  OM were chamomile [23], calendula [11], 
aloe, curcumin [24], honey [14, 24, 25, 26], as well as vitamins 
C and E [13, 22, 26, 27].
Chamomile (Matricaria recutita) has the ability of inhi-
biting cyclooxygenase, 5-lipoxygenase and prostaglandins, 
and thus has anti-inflammatory and anti-microbic properties. 
It alleviates burning sensation and pain [9] and also has an 
anti-oxidating action, thus decreasing the amount of IL-1b 
and TNF-α [23].
Aloe (Aloe vera) has antipruritic, moisturising, anti-inflam-
matory and astringent properties. It is also a source of mine-
rals, amino-acids, vitamins and fatty acids; moreover it is an 
immunostimulant with anti-cancer activity properties[9, 24].
Vitamin E has strong antioxidant action [26].




0 no lesions 
1 pain, erythema 
2 erythema, erosions – yet the patient is able to eat solid 
food 
3 ulceration – liquid diet is required 
4 the patient is unable to consume fluids – parenteral 
nutrition 
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radiotherapy, as an independent treatment, up to a dose of  50 
Gy [32]. It is also advisable to rinse the oral cavity with saline 
and calcium bicarbonate as this facilitates the maintenance of 
the correct oral hygiene for patients [28]. That said, similarly to 
the previous guidelines, chlorhexidine is not recommended 
as a mouth wash [28]. 
The MSCC/ISOO guidelines from 2014 concerning the 
prevention of oral mucositis in patients undergoing high-
-dose chemotherapy and whole body irradiation, before an 
autologous transplant of stem cells in the treatment of haema-
tological cancers, recommend the use of palifermin [6, 8, 16]. 
Palifermin is a recombined human keratinocyte growth factor 
(KGF1), which affects the growth and differentiation of epithe-
lial cells, playing also a role in inhibiting the process of apopto-
sis [5]. In spite of the promising results of the trials concerning 
the efficacy of this medication in OM prevention [22, 33, 34], 
there are also published reports about the adverse effects of 
this drug on cancers of the head and neck area treated with 
combined chemotherapy [35]. 
As a result of radiotherapy, reactive oxygen species (ROS) 
are produced which damage the cells of the mucous membra-
ne. For the treatment of this condition, there were attempts to 
use the anti-oxidation enzyme: superoxide dismutase (SOD). 
A derivative of SOD, based on manganese, was produced and 
named GC4419 – this substance has the ability to dissociate 
superoxide anions [5]. Barbor et al. described the beneficial 
the effect of this substance [36], including the results of the 
studies carried out by Anderson et al. are promising. In patients 
undergoing combined chemotherapy, after an intravenous 
administration of  SOD, the intensification and duration of OM 
was decreased [37].  
It must be remembered that it is prophylaxis that plays 
the key role in patients undergoing radiotherapy. That is why 
a patient qualified for irradiation of the head and neck area 
requires a thorough dental assessment and detailed instruc-
tions concerning oral hygiene. Correct oral care makes up 
a significant element of cancer patient treatment. Oral cavity 
hygenisation in order to remove potential inflammatory foci, 
requires the folowing procedures:
• completed treatment of cavities resulting from caries, 
• correction of sharp filling edges, 
• extraction of teeth not qualified for further treatment, and
• treatment of other inflammations within the oral cavity
It is necessary to control, and, if necessary, correct dentures 
and also to inform patients about nutritional requirements 
during radiotherapy. Sour, hot and overly hard products are 
not recommended. A large amount of fluid intake is recom-
mended. The priority is to prevent any inflammatory condition 
within the oral mucosa as during anti-cancer treatment it is 
subject to irradiation. During oncological treatment the patient 
should be under the regular supervision of their dentist, so that 
a quick intervention in the case of inflammatory lesions within 
the oral cavity is possible [11].
Tables III and IV present detailed recommendations concer-
ning prophylaxis and treatment in patients with symptoms of 
OM after radiotherapy, based on the selected, leading clinical 
recommendations [38].
For many years OM has been in the interest of dental as-
sociations. In 2015 the recommendation of the Polish Group 
of Specialists in Prophylaxis and Treatment of Complications 
within the Oral Cavity was published. The prophylactic and tre-
atment procedures connected with irradiation were discussed 
in detail in this publication. These recommendations, in a brief 
from are presented in table V [39].
In 2009 Pytko-Polończyk proposed an algorithm of dental 
care in patients undergoing radio- and chemotherapy [40]. 
Table II. Interventions connected with radiotherapy in patients with head and neck cancer, published by MASCC/ISOO – guidelines update from 2019 [28–32] 
Intervention Guideline
Photo-biomodulation – laser and other light 
therapies, intraoral low-power laser therapy
• OM prevention in patients with head and neck cancers:
– radiotherapy: change of the guidelines from suggestions to recommendations;
– patients in chemotherapy: novelty – use recommendation
• OM treatment: no guidelines
Glutamine – oral • OM prevention in patients with head and neck cancer:
– radiotherapy: no guidelines
– radio-chemotherapy – use suggestion 
Elemental diet • no guidelines 
Zinc • OM prevention in patients with head and neck cancer:
– radio- or radio-chemotherapy: change – currently no guidelines 
Supplements: vitamin E, selenium, folic acid, calcitriol • no guidelines 
Rinsing oral cavity with benzydamine • OM prevention in patients with head and neck cancer:
– radiotherapy, dose up to 50 Gy: confirmation of the previous guidelines – rinsing oral 
cavity with benzydamine 
– radio-chemotherapy: use suggestion
• OM treatment:
– radiotherapy: no guidelines 
– radio-chemotherapy: no guidelines
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Table III. The comparison of the methods of oral mucositis (OM) prevention [38]
Before the commencement of anti-cancer treatment 
• dental treatment 
• prospective tooth extractions – 10–14 days before the planned radiotherapy 
During radiotherapy and after its completion  (for ≥2 weeks) 
• washing teeth with a toothpaste and soft toothbrush (regularly exchanged ) ≥3 times per day  
• using dental floss
• frequent drinking of small amounts of water and/or rinsing oral cavity with 0.9% saline, sodium bicarbonate or liquid containing benzydamine 
(Hascosept, Tantum verde) – 4–6 times per day 
• not using the solutions of chlorhexidine and alcohol 
Absolutely forbidden
• tobacco smoking 
• alcohol consumption 
• hot spices 
• tough food
It is recommended to use ice cubes (only when there oral mucosa is not damaged)
Table IV. The treatment of the patients with OM symptoms [38]
Symptom Recommendations 
Oral cavity dryness  • sugar-free chewing gum, sugar-free sweets
• rinsing oral cavity with 0.9% NaCl solution or sodium bicarbonate  
• artificial saliva 
Mild to moderate pain • local agents – benzocaine or benzydamine (used a few times per day onto the affected oral 
mucosa)
Strong pain  • analgesic treatment according to the WHO recommendations or rinsing with 0.2% morphine 
solution or 0.5% doxepin oral solution.
Suspected infection • a swab followed by empirical treatment with a broad- spectrum antibiotic (aminoglycoside or 3rd 
generation cephalosporin)
Suspected oral candidiasis • anti-fungal treatment 
Inability of oral consumption  • parenteral nutrition to be considered 
Irrespectively of symptoms • zinc supplementation to be considered 
Table V. Recommendation of the  Polish Group of Specialists in Prophylaxis and Treatment of Complications within the Oral Cavity [39]
Prophylaxis before treatment • oral hygiene (brushing teeth 3 times per day with a very soft toothbrush, rinsing oral cavity with 0.9% 
NaCl solution or with baking soda solution – 1 teaspoonful per 100 ml of boiled water, flossing)
• temporary removal of orthodontic appliance 
• limitation of use of movable dentures 
• dietary recommendations
• evaluation of the patient’s nutrition status and, if necessary, gastrostomy tube feeding 
Preparation to head and neck 
irradiation 
• evaluation of the condition of oral cavity, orthopantomogram
• hygenisation of oral cavity 
• conservative treatment, periodontology treatment with post-extraction wound dressing 
• evaluation of prosthetic restorations 
• removal of permanent dentures 
Patients in radiotherapy or 
chemotherapy – prophylaxis  
• proper oral hygiene 
• brushing teeth with a soft toothbrush 
• dental flosses 
• cleaning of movable prosthetic restorations, at night – storing dentures in dry conditions 
• oral cavity rinsing with 0.9% NaCl solution or baking soda solution – 5 times/day
• oral cavity rinsing with benzydamine 4 times/day
• oral cavity rinsing with – Caphosol solution 4–6 times/day
• oral cavity rinsing with – complex preparations – Alpha Med, laryngology mix
• secretion diluting agents 
• fluoridation 
• dietary consultation 
Patients in radiotherapy or 
chemotherapy – treatment  
• fungal infection – fluconazole 200–400 mg/day, nystatin – 5 times/day 
• bacterial infection – antibiotic therapy according to the antibiogram or empirical 
• Caphosol – rinsing oral cavity – 6–10 times/day
• benzydamine – 4 times/day
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Knowledge of the general principles of dental management in 
such patients should be, at least in general, known to oncology 
specialists, as this is an element of multispecialist patient care 
in cases of malignant cancers. 
In the first period, before the commencement of an-
ti-cancer treatments, a  decontamination of the oral cavity 
should be performed. This process should be completed at 
least one week before the start of oncological treatment. This 
process comprises professional hygienisation procedures con-
nected with detailed instructions for the patient, the remov-
al of foci of inflammation and caries, filling the cavities and 
elimination of all traumatising factors. In the second period, 
during the anti-cancer treatment, a proper collaboration be-
tween the dentist and the oncology specialist is necessary. 
The procedures comprise the use of agents treating local 
lesions in the mucosa, including the first symptoms of OM 
and also the use of medication to alleviate xerostomia. The 
drugs which alleviate such lesions comprise a protein-free di-
alysate of calf blood (Solcoseryl paste; Meda), vitamin A + D3 
in a fluid form, dental washes containing herbal mix, allantoin, 
D-panthenol, linseed (e.g. Alfa-med Atos, Alfa-implant Atos), 
a solution of calcium-phosphate ions (Caphosol [7, 40], Fomu-
cal [41]). Also fluids containing benzydamine have a beneficial 
effect (Hascosept, Tantum verde) [38]. Often in patients after 
oncological treatment, it is necessary to introduce antibacterial 
and/or anti-mycotic treatments. It is recommended to have 
a low-carbohydrate diet, rich in vegetables and fruit, kephir and 
milk. The use of vitamin B is also helpful. The third period of 
dental care begins after the completion of oncological thera-
py, and is comprised of the continuation of the collaboration 
between the dentist and the patient, motivating them to 
maintain correct oral hygiene, the elimination of radiotherapy 
side-effects, such as: xerostomia, candidosis, bacterial infec-
tions. The patient should visit their dentist every one to three 
months and, then every three to six months [7, 40].
Conclusions 
Dentists play an important role in the prophylaxis of OM, 
especially in the multispecialist treatment of patients with 
cancers of the head and neck region who have developed 
symptoms of oral mucositis. That is why it is justifiable that 
oncological centres should create specialist teams, consisting 
of an oncologist, a dentist and a nurse. The members of these 
teams could provide multidisciplinary care to patients with 
head and neck cancers with regards to the prevention of OM 
and the treatment of this complication within the oral cavity.
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